ClinicalTrials.gg
CompletedNCT02223065Updated Apr 27, 2016Results posted

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

A Phase 1 interventional study of Saxagliptin and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
53rd of 74
36 · median 138
Started
2014
with 9 others
Phase 1
14 of 74
none open now
Registered
52nd of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 53rd largest by enrollment, is one of 10 that started in 2014, is one of 14 in phase 1, and was the 52nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy subjects.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form

    • Signed written informed consent must be obtained from the subjects in accordance with requirements of the study center's IRB or IEC before the initiation of any protocol-required procedures.
  2. Target Population

    • Healthy subjects as determined by no deviation from normal in medical history, psychiatric history, physical examination findings, vital sign measurements, 12-lead measurements, physical measurements, and clinical laboratory test results.
  3. Age and Reproductive Status

    • Males and females, ages 19 to 55 years, inclusive. To extent possible, the distribution of men and women between the sequences will be balanced
    • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
    • Women must not be breastfeeding. d) WOCBP must agree to follow instructions for method(s) of for the duration of treatment with study drugs saxagliptin and dapagliflozin plus 5 half lives of study drug dapagliflozin (the longer half life between the 2 drugs; 3 days) for a total of 3 days following treatment completion.

      e) Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drugs saxagliptin and dapagliflozin plus 5 half lives of dapagliflozin (the longer half life between the 2 drugs; 3 days) for a total of 3 days following treatment completion.

      f) Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described in this section

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug
  • Any other sound medical, psychiatric, and/or social reason as determined by the investigator
  • Any major surgery within 4 weeks of study drug administration.
  • Any prior GI surgery including cholecystectomy (remote history of appendectomy will not be exclusionary).
  • Current, recent (within 3 months of study drug administration), or remote history of pancreatitis.
  • Donation of blood or plasma to a blood bank or in a clinical study (except at screening visit) within 4 weeks before study drug administration.
  • Blood transfusion within 4 weeks of study drug administration. h) Inability to tolerate oral medication.
  • Inability to be venipunctured performed and/or tolerate venous access.
  • Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, e-cigarettes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months before check-in.
  • Drug or alcohol abuse (within 2 years of study drug administration) as defined in the - 4th Edition, Diagnostic Criteria for Drug and Alcohol Abuse History of glucose intolerance or diabetes mellitus.
  • For females, history of chronic or recurrent urinary tract infection (UTI) (defined as 3 occurrences per year) or UTI in the past 3 months. For males, any UTI within the previous 5 years that has not been thoroughly evaluated and for which an explanation is not clear.
  • History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections.
  • Any other sound medical, psychiatric, and/or social reason as determined by the investigator.

Physical and Laboratory Test Findings

  1. Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, ECGs, or clinical laboratory determinations beyond what is consistent with the target population.
  2. Abnormal urinalysis at screening (may repeat once). If the urinalysis is abnormal on Day -1 of Period 1, continuation in the study is up to the investigator's discretion. The CRO medical monitor should be consulted.
  3. Glucosuria or hematoria at screening or Day -1 of Period 1, repeat is not permitted. d) A positive nicotine test (ie, cotinine).

e) Abnormal liver function tests (alanine or [ALT or AST, respectively], or total ).

f) Any of the following on 12-lead prior to study drug administration, confirmed by repeat.

i) PR ≥ 210 ms ii) QRS ≥ 120 ms iii) ≥ 500 ms iv) QTcF ≥ 450 ms g) Positive urine screen for drugs of abuse. h) Positive urine alcohol test. i) Positive blood screen for virus (HCV) antibody, surface antigen (HBsAg), or (HIV)-1 or HIV-2 antibodies at screening.

  1. Allergies and Adverse Drug Reaction

    1. History of allergy or adverse reactions to DPP4 or SGLT inhibitors or related compounds.
    2. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).
  2. Other Exclusion Criteria

    1. Prisoners or subjects who are involuntarily incarcerated.
    2. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
    3. Inability to comply with restrictions and prohibited activities/treatments
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    Treatment B

    Single oral dose of FDC (fixed-dose combination) tablet

    Drug: Saxagliptin · Drug: Dapagliflozin

Interventions

  • Also known as: Onglyza

  • Also known as: Farxiga in the United States, Forxiga in other countries

06

What researchers measure

Primary outcomes

  1. Saxagliptin Maximum Observed Concentrations (Cmax)

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1-3 (Period 1) and Day 8-10 (Period 2)

  2. Dapagliflozin Maximum Observed Concentrations (Cmax)

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1 to 3 (Period 1) and Day 8 to 10 (Period 2)

  3. Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1-3 (Period 1) and Day 8-10 (Period 2)

  4. Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1-3 (Period 1) and Day 8-10 (Period 2)

  5. Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1-3 (Period 1) and Day 8-10 (Period 2)

  6. Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])

    5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

    Time frame: Day 1-3 (Period 1) and Day 8-10 (Period 2)

07

Results

Posted Apr 27, 2016

Participant flow

Open-label, randomized, single-dose, 2-treatment, 2-period crossover study in 36 healthy subjects. A single dose was administered on Day 1 and Day 8 under fasted conditions. Blood samples for the plasma pharmacokinetic analysis collected over a 60-hour interval after dosing in each period

Participant flow — Overall Study
MilestoneTreatment ABTreatment BA
Started1818
Completed1818
Not completed00

Outcome measures

PrimarySaxagliptin Maximum Observed Concentrations (Cmax)

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1-3 (Period 1) and Day 8-10 (Period 2)
Reported as:
Geometric mean · ng/mL
Saxagliptin Maximum Observed Concentrations (Cmax)
ng/mLTreatment ATreatment B
Saxagliptin Maximum Observed Concentrations (Cmax)26.2 ± 5.72325.5 ± 5.763
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.4950 · Geometric mean ratio: 0.975 · 90% CI 0.915 to 1.038
PrimaryDapagliflozin Maximum Observed Concentrations (Cmax)

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1 to 3 (Period 1) and Day 8 to 10 (Period 2)
Reported as:
Geometric mean · ng/mL
Dapagliflozin Maximum Observed Concentrations (Cmax)
ng/mLTreatment ATreatment B
Dapagliflozin Maximum Observed Concentrations (Cmax)142 ± 28.93141 ± 37.10
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.8650 · Geometric mean ratio: 0.993 · 90% CI 0.932 to 1.060
PrimarySaxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1-3 (Period 1) and Day 8-10 (Period 2)
Reported as:
Geometric mean · ng.h/mL
Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])
ng.h/mLTreatment ATreatment B
Saxagliptin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])95.9 ± 5.72398.0 ± 5.763
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.2344 · Geometric mean ratio: 1.022 · 90% CI 0.991 to 1.054
PrimaryDapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1-3 (Period 1) and Day 8-10 (Period 2)
Reported as:
Geometric mean · ng.h/mL
Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])
ng.h/mLTreatment ATreatment B
Dapagliflozin AUC From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-T])537 ± 5.723546 ± 5.763
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.2458 · Geometric mean ratio: 1.016 · 90% CI 0.993 to 1.038
PrimarySaxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1-3 (Period 1) and Day 8-10 (Period 2)
Reported as:
Geometric mean · ng.h/mL
Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])
ng.h/mLTreatment ATreatment B
Saxagliptin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])97.0 ± 5.72399.4 ± 5.763
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.1947 · Geometric mean ratio: 1.024 · 90% CI 0.993 to 1.056
PrimaryDapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])

5-mg saxagliptin/10-mg dapagliflozin as a Fixed-dose Combination (FDC) and as Individual Tablets together in the fasted state

Time frame:
Day 1-3 (Period 1) and Day 8-10 (Period 2)
Reported as:
Geometric mean · ng.h/mL
Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])
ng.h/mLTreatment ATreatment B
Dapagliflozin AUC From Time 0 Extrapolated to Infinite Time (AUC[0-inf])553 ± 5.723561 ± 5.763
Statistical analysis
  • Treatment A vs Treatment B · ANOVA · p = 0.3191 · Geometric mean ratio: 1.013 · 90% CI 0.992 to 1.034

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/36 (0%)0/36 (0%)
Treatment B—0/36 (0%)0/36 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Treatment ABTreatment BATotal
Mean33.6 ± 11.6332.9 ± 11.3433.3 ± 11.32
Age, Customized
Age, Customized(Participants)Treatment ABTreatment BATotal
< 65181836
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ABTreatment BATotal
Female81018
Male10818
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment ABTreatment BATotal
BLACK/AFRICAN AMERICAN213
WHITE161733
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2014
First posted
Aug 22, 2014
Start
Sep 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Apr 27, 2016
Last update
Apr 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02223065
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 22, 2014
Start date
Sep 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Apr 27, 2016
Last update
Apr 27, 2016

Study contacts

Michael Gartner, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Dapagliflozin

Start the discussion